Brief: Shattuck Labs To Present Complete Dose-Escalation Data From Phase 1A Monotherapy Clinical Trial Of Sl-172154 In Platinum-Resistant Ovarian Cancer (PROC)
25/05/2023 23:11
May 25 (Reuters) - Shattuck Labs Inc STTK.O :
* SHATTUCK LABS TO PRESENT COMPLETE DOSE-ESCALATION DATA
FROM
PHASE 1A MONOTHERAPY CLINICAL TRIAL OF SL-172154 IN
PLATINUM-RESISTANT OVARIAN CANCER (PROC) AT THE AMERICAN SOCIETY
OF CLINICAL ONCOLOGY (ASCO) 2023 ANNUAL MEETING
Source text for Eikon: ID:nGNX6RPFzV
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shattuck Labs
See all newsBrief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
Shattuck Labs Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health